Insulet Corp. closed 7.87% below its 52-week high of $289.46, which the company achieved on February 7th.

Insulet's impressive growth with its Omnipod system, robust 2024 results, and surging valuation make it attractive. See more ...

Insulet Corporation (PODD) continues its strong sales and growth trend.

Insulet (NASDAQ:PODD – Get Free Report) was upgraded by StockNews.com from a “hold” rating to a “buy” rating in a research ...

Insulet (NASDAQ:PODD – Get Free Report) had its price objective boosted by analysts at Piper Sandler from $285.00 to $310.00 ...

Insulet Corporation (NASDAQ:PODD) reported fourth-quarter adjusted EPS of $1.15, down from $1.40 a year ago but beating the ...

Bernstein raised the firm’s price target on Insulet (PODD) to $335 from $315 following a strong quarter and an “impressive” outside-U.S.

Insulet reported a higher-than-expected profit in the fourth quarter on Thursday, driven by strong demand for its wearable insulin pumps.

In a report released today, Patrick Wood from Morgan Stanley maintained a Sell rating on Glaukos (GKOS – Research Report), with a price target ...

Insulet (PODD) delivered earnings and revenue surprises of 9.52% and 2.73%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Insulet's Strong Q4 Highlights Surging Omnipod Demand And Growth Potential: Analyst On Thursday, Insulet Corporation (NASDAQ:PODD) reported fourth-quarter adjusted EPS of $1.15, down from $1.40 a ...

Learn more about whether Koninklijke Philips N.V. or Insulet Corporation is a better investment based on AAII's A+ Investor ...